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Objective
We characterized the effect of mometasone furoate/
formoterol (MF/F) treatment on nocturnal awakenings
requiring rescue-medication (SABA) use in three Phase
III efficacy trials (baseline=awakenings in wk prior to
first dose; endpoint=awakenings across entire treat-
ment period).
Methods
Subjects were asthmatics previously using low- (n=746),
medium- (n=781) or high-dose (n=728) inhaled corti-
costeroids ICS. Low-dose subjects were randomized to
26-wk treatment with MF/F 100/10µg, MF 100µg,
F 10µg, or placebo; medium-dose subjects to 26-wk
treatment with MF/F 200/10µg, MF 200µg, F 10µg, or
placebo; high-dose subjects to 12-wk treatment with
MF/F 400/10µg, MF/F 200/10µg, or MF 400µg. All
treatments were delivered twice-daily via metered-dose
inhaler.
Results
Baseline awakenings ranged from 0.84–1.05 (MF/F 100/
10μg study), 1.05–1.26 (MF/F 200/10μg study), and 1.33–
1.61 nights/wk (MF/F 400/10μg and 200/10μg study).
Nocturnal awakenings were reduced by MF/F 100/10μg=–
0.42, MF 100μg=–0.21, F 10μg=–0.21, and placebo=0.14
nights/wk; changes in the other placebo-controlled study
were MF/F 200/10μg=–0.56, MF 200μg=–0 . 3 5 ,F1 0 μg=
+0.07 and placebo=0.00 night/wk, respectively. In both of
these studies MF/F was superior to placebo (P<.001) and F
(P=.035); MF was also superior to F and placebo. In the
non-placebo controlled study, awakenings were reduced
by –0.70, –0.70 and –0.35 nights/week by MF/F 200/10μg,
MF/F 400/10μga n dM F4 0 0 μg, respectively; both MF/F
treatments were superior to MF (P≤.006).
Conclusions
Both MF/F and MF significantly reduced nocturnal-awa-
kenings compared with F and placebo. Both doses of
MF/F were superior to MF in the non-placebo controlled
study.
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